While the roles of ERα and ERβ in hormone-dependent diseases such as breast and prostate cancers are becoming increasingly elucidated, with ERα having a proliferative and ERβ having an anti-proliferative role, the mechanism by which these two receptors interact with each other in both normal and diseased states has remained elusive. Here, ESR2 is linked to prostate cancer.